Compare EVI & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVI | ANNX |
|---|---|---|
| Founded | 1959 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.9M | 730.4M |
| IPO Year | 1995 | 2020 |
| Metric | EVI | ANNX |
|---|---|---|
| Price | $19.91 | $5.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $35.00 | $16.50 |
| AVG Volume (30 Days) | 30.3K | ★ 2.2M |
| Earning Date | 05-21-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.73% | N/A |
| EPS Growth | 32.43 | ★ 42.94 |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $389,830,000.00 | N/A |
| Revenue This Year | $15.53 | N/A |
| Revenue Next Year | $3.83 | N/A |
| P/E Ratio | $73.19 | ★ N/A |
| Revenue Growth | ★ 10.26 | N/A |
| 52 Week Low | $14.99 | $1.29 |
| 52 Week High | $34.82 | $7.18 |
| Indicator | EVI | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 47.53 | 53.33 |
| Support Level | $18.23 | $4.77 |
| Resistance Level | $21.01 | $7.18 |
| Average True Range (ATR) | 1.14 | 0.36 |
| MACD | 0.17 | 0.06 |
| Stochastic Oscillator | 53.46 | 50.97 |
EVI Industries Inc through its subsidiaries, is a distributor that sells, leases, and rents commercial, industrial, and vended laundry and dry cleaning equipment and steam and hot water boilers manufactured by others, supplies related replacement parts and accessories, designs and plans turn-key laundry, dry cleaning, and boiler systems, and provides installation and maintenance services to its customers, which include commercial, industrial, institutional, government, and retail customers. These activities are conducted in the United States, Canada, the Caribbean, and Latin America.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.